FDA accepts Pfizer's new CRC drug application & more: 3 GI industry key notes

Written by Eric Oliver | January 02, 2020 | Print  |

Here are three updates from gastroenterology companies and practices from the past week:

The FDA accepted Pfizer's supplemental New Drug Application for its combination therapy for advanced BRAF-mutant metastatic colorectal cancer and granted it priority review designation.

Check-Cap reported final results from its U.S. pilot study of its C-Scan System, a preparation-free colorectal cancer detection system.

Hattiesburg, Miss.-based Forrest General Hospital added Porter Glover, MD, Telciane Vesa, MD, and Andrew Weeks, MD, to its gastroenterology care team.

More articles on surgery centers:
Robotics might not be worth the 'tremendous' investment for ASCs — 2 leaders explain why
12 ASCs adding total joint replacements in 2019
Crystal Clinic Orthopedic Center celebrates northeast Ohio opening

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.